Why Are Digital Health Policies Crucial?
J Med Econ. 2024 Jan 4:1-6. doi: 10.1080/13696998.2024.2302254. Online ahead of print.NO ABSTRACTPMID:38174851 | DOI:10.1080/13696998.2024.2302254 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 4, 2024 Category: Health Management Authors: Ahmad Z Al Meslamani Source Type: research
Adverse events and costs among non-metastatic castration-resistant prostate cancer patients
CONCLUSION: There is significant HCRU and cost burden among nmCRPC patients treated with ARAs developing AEs, highlighting the need for treatments with improved tolerability. Additional studies are warranted to include recently approved agents.PMID:38174553 | DOI:10.1080/13696998.2023.2299179 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 4, 2024 Category: Health Management Authors: Sreevalsa Appukkuttan Jianying Yao Jamie Partridge Sheldon X Kong Jacqueline Parkin Stephen J Freedland Source Type: research
Why Are Digital Health Policies Crucial?
J Med Econ. 2024 Jan 4:1-6. doi: 10.1080/13696998.2024.2302254. Online ahead of print.NO ABSTRACTPMID:38174851 | DOI:10.1080/13696998.2024.2302254 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 4, 2024 Category: Health Management Authors: Ahmad Z Al Meslamani Source Type: research
Adverse events and costs among non-metastatic castration-resistant prostate cancer patients
CONCLUSION: There is significant HCRU and cost burden among nmCRPC patients treated with ARAs developing AEs, highlighting the need for treatments with improved tolerability. Additional studies are warranted to include recently approved agents.PMID:38174553 | DOI:10.1080/13696998.2023.2299179 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 4, 2024 Category: Health Management Authors: Sreevalsa Appukkuttan Jianying Yao Jamie Partridge Sheldon X Kong Jacqueline Parkin Stephen J Freedland Source Type: research
Why Are Digital Health Policies Crucial?
J Med Econ. 2024 Jan 4:1-6. doi: 10.1080/13696998.2024.2302254. Online ahead of print.NO ABSTRACTPMID:38174851 | DOI:10.1080/13696998.2024.2302254 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 4, 2024 Category: Health Management Authors: Ahmad Z Al Meslamani Source Type: research
Adverse events and costs among non-metastatic castration-resistant prostate cancer patients
CONCLUSION: There is significant HCRU and cost burden among nmCRPC patients treated with ARAs developing AEs, highlighting the need for treatments with improved tolerability. Additional studies are warranted to include recently approved agents.PMID:38174553 | DOI:10.1080/13696998.2023.2299179 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 4, 2024 Category: Health Management Authors: Sreevalsa Appukkuttan Jianying Yao Jamie Partridge Sheldon X Kong Jacqueline Parkin Stephen J Freedland Source Type: research
Why Are Digital Health Policies Crucial?
J Med Econ. 2024 Jan 4:1-6. doi: 10.1080/13696998.2024.2302254. Online ahead of print.NO ABSTRACTPMID:38174851 | DOI:10.1080/13696998.2024.2302254 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 4, 2024 Category: Health Management Authors: Ahmad Z Al Meslamani Source Type: research
Adverse events and costs among non-metastatic castration-resistant prostate cancer patients
CONCLUSION: There is significant HCRU and cost burden among nmCRPC patients treated with ARAs developing AEs, highlighting the need for treatments with improved tolerability. Additional studies are warranted to include recently approved agents.PMID:38174553 | DOI:10.1080/13696998.2023.2299179 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 4, 2024 Category: Health Management Authors: Sreevalsa Appukkuttan Jianying Yao Jamie Partridge Sheldon X Kong Jacqueline Parkin Stephen J Freedland Source Type: research
Why Are Digital Health Policies Crucial?
J Med Econ. 2024 Jan 4:1-6. doi: 10.1080/13696998.2024.2302254. Online ahead of print.NO ABSTRACTPMID:38174851 | DOI:10.1080/13696998.2024.2302254 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 4, 2024 Category: Health Management Authors: Ahmad Z Al Meslamani Source Type: research
Cost-effectiveness analysis of upadacitinib as a treatment option for patients with rheumatoid arthritis in the Kingdom of Saudi Arabia
CONCLUSION: Upadacitinib as 1 L treatment in moderate-to-severe RA can considerably reduce healthcare resource burden in KSA, majorly due to reduced drug administration/monitoring/hospitalization/surgical and indirect costs.PMID:38163926 | DOI:10.1080/13696998.2023.2299176 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 2, 2024 Category: Health Management Authors: Hana Al-Abdulkarim Yuvraj Sharma Suzan M Attar Waleed Husain Ibrahim Al-Homood Bedor Al Omari Omneya Mohamed Mai Alsaqa'aby Ahmed M Jaheen Ali Anwar Tharwat M Hamad Zeyad Alzahrani Source Type: research
A cost-effectiveness analysis of intrauterine spacers used to prevent the formation of intrauterine adhesions following endometrial cavity surgery
CONCLUSION: This analysis robustly demonstrated that intrauterine spacers would be cost-saving to healthcare payers, including both per-patient and per-plan member, through a reduction in IUAs and improvements to patients' pregnancy-related outcomes.PMID:38131367 | DOI:10.1080/13696998.2023.2298584 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 22, 2023 Category: Health Management Authors: Luke Schmerold Coby Martin Aashay Mehta Dhruv Sobti Ajit Kumar Jaiswal Jatinder Kumar Ian Feldberg Malcolm G Munro Won Chan Lee Source Type: research
